Skip to main content
. 2019 Apr;25(4):10.18553/jmcp.2018.18308. doi: 10.18553/jmcp.2018.18308

Table 1.

Overview of Biologic Treatment Pattern Subgroups in Patients with Moderate to Severe Psoriasisa

Group Overall N = 8,710 Adalimumab n = 4,298 Etanercept n = 2,795 Infliximab n = 161 Ustekinumab n = 1,465
Patients, n (%) 8,710 (100.0) 4,289 (49.2) 2,795 (32.1) 161 (1.8) 1,465 (16.8)
  Nonswitchers 5,000 (57.4) 2,436 (56.8) 1,458 (52.2) 100 (62.1) 1,006 (68.7)
  Switchers 1,001 (11.5) 543 (12.7) 359 (12.8) 25 (15.5) 74 (5.1)
  Discontinuers 2,709 (31.1) 1,310 (30.5) 978 (35.0) 36 (22.4) 385 (26.3)

aPercentages for treatment pattern subgroups were calculated from the total number of patients who initiated each therapy.